The Johns Hopkins Multiple Sclerosis Center seeks to provide an accurate diagnosis and an effective treatment plan to help patients properly manage multiple sclerosis (MS).
Request an Appointment
We make it easy, even from out-of-state.
Call now
Clinicoradiological Paradox
What is underlying MS? It's more than counting the lesions.
Read more
Project RESTORE
Learn more about the relationship between multiple sclerosis and transverse myelitis.
We Are Here For You
The diagnosis of multiple sclerosis can be a difficult process for the individual who is experiencing unusual and worrisome symptoms — other diseases have similar warning signs, and early symptoms can be mild, non-specific and sporadic. To date, there is no definitive single laboratory test to confirm MS, thus a confirmed diagnosis can only be made through a careful medical history, a detailed neurological examination, MRI imaging and often a test of spinal fluid and a host of blood tests to exclude other possible causes of the neurological symptoms.
As one of the largest clinical and research MS centers in the world, we focus on all aspects of the disease — from diagnosis and life-long quality clinical care to cutting edge clinical trials, brain imaging and laboratory research.
Learn more:
- What is multiple sclerosis?
- Symptoms and causes of MS
- Diagnosing MS
- Treating MS
- New Oral Medication for MS is approved by FDA
For more information, contact the Johns Hopkins Multiple Sclerosis Center at 410-955-9441.
Patients: In May, 2012 the U.S. Food and Drug Administration issued a safety communication to inform people with MS and healthcare providers about potential risks of treatment procedures and devices being used to treat a condition known as CCSVI (chronic cerebrospinal venous insufficiency). The agency reviewed these risks and encourages additional research to provide a more complete understanding of what the relationship might be between CCSVI and MS so as to help assist in more informed treatment decisions. To read the full communication on the FDA's site please click here.




